Neurology

>

Latest News

Discussing phase 3 data of Panzyga for PANS, with Michael Daines, MD
Discussing phase 3 data of Panzyga for PANS, with Michael Daines, MD

June 19th 2025

In this video interview, Michael Daines, MD, explains phase 3 data for Panzyga (Octapharma) for pediatric acute- onset neuropsychiatric syndrome (PANS).

A headache with a red flag in a 10-year-old girl
A headache with a red flag in a 10-year-old girl

June 18th 2025

Phase 3 trial of omaveloxolone to treat Friedreich ataxia in children aged 2 to <16 begins | Image Credit: © 125154153 - stock.adobe.com.
Phase 3 trial of omaveloxolone to treat Friedreich ataxia in children aged 2 to <16 begins

June 18th 2025

Full recap from the 2025 Pediatric Academic Societies meeting |  Image Credit: © SCStock - © SCStock - stock.adobe.com.
Full recap from the 2025 Pediatric Academic Societies meeting

May 1st 2025

Youth with neurodevelopmental disabilities face higher risk of poor cardiovascular health | Image Credit: © adobedesigner - stock.adobe.com.
Youth with neurodevelopmental disabilities face higher risk of poor cardiovascular health

April 26th 2025

More News

© 2025 MJH Life Sciences

All rights reserved.